nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—DRD1—nerve—acquired immunodeficiency syndrome	0.00617	0.0269	CbGeAlD
Loxapine—HTR3A—nerve—acquired immunodeficiency syndrome	0.00596	0.026	CbGeAlD
Loxapine—HTR5A—nervous system—acquired immunodeficiency syndrome	0.00557	0.0243	CbGeAlD
Loxapine—HTR5A—central nervous system—acquired immunodeficiency syndrome	0.00536	0.0234	CbGeAlD
Loxapine—HRH4—blood—acquired immunodeficiency syndrome	0.005	0.0218	CbGeAlD
Loxapine—SLC6A3—nerve—acquired immunodeficiency syndrome	0.00496	0.0216	CbGeAlD
Loxapine—HRH4—bone marrow—acquired immunodeficiency syndrome	0.00484	0.0211	CbGeAlD
Loxapine—HTR5A—brain—acquired immunodeficiency syndrome	0.00426	0.0186	CbGeAlD
Loxapine—SLC6A2—nerve—acquired immunodeficiency syndrome	0.004	0.0174	CbGeAlD
Loxapine—HTR7—nerve—acquired immunodeficiency syndrome	0.00385	0.0168	CbGeAlD
Loxapine—DRD2—nerve—acquired immunodeficiency syndrome	0.00364	0.0159	CbGeAlD
Loxapine—SLC6A4—blood plasma—acquired immunodeficiency syndrome	0.00344	0.015	CbGeAlD
Loxapine—HTR7—endothelium—acquired immunodeficiency syndrome	0.00328	0.0143	CbGeAlD
Loxapine—HTR1A—blood plasma—acquired immunodeficiency syndrome	0.00305	0.0133	CbGeAlD
Loxapine—HTR7—blood plasma—acquired immunodeficiency syndrome	0.00292	0.0127	CbGeAlD
Loxapine—HRH2—skin of body—acquired immunodeficiency syndrome	0.00276	0.012	CbGeAlD
Loxapine—CHRM5—skin of body—acquired immunodeficiency syndrome	0.00263	0.0115	CbGeAlD
Loxapine—HTR2A—nerve—acquired immunodeficiency syndrome	0.0024	0.0105	CbGeAlD
Loxapine—DRD5—lymphoid tissue—acquired immunodeficiency syndrome	0.00238	0.0104	CbGeAlD
Loxapine—HTR1E—nervous system—acquired immunodeficiency syndrome	0.00238	0.0104	CbGeAlD
Loxapine—HTR1E—central nervous system—acquired immunodeficiency syndrome	0.00229	0.00998	CbGeAlD
Loxapine—HRH2—digestive system—acquired immunodeficiency syndrome	0.0022	0.00961	CbGeAlD
Loxapine—ADRA2A—blood plasma—acquired immunodeficiency syndrome	0.00214	0.00932	CbGeAlD
Loxapine—DRD4—brain—acquired immunodeficiency syndrome	0.00211	0.00919	CbGeAlD
Loxapine—HRH2—blood—acquired immunodeficiency syndrome	0.0021	0.00916	CbGeAlD
Loxapine—CHRM4—nervous system—acquired immunodeficiency syndrome	0.00208	0.00909	CbGeAlD
Loxapine—HTR2A—endothelium—acquired immunodeficiency syndrome	0.00205	0.00893	CbGeAlD
Loxapine—CHRM4—central nervous system—acquired immunodeficiency syndrome	0.00201	0.00875	CbGeAlD
Loxapine—DRD3—nervous system—acquired immunodeficiency syndrome	0.00194	0.00845	CbGeAlD
Loxapine—DRD3—central nervous system—acquired immunodeficiency syndrome	0.00187	0.00813	CbGeAlD
Loxapine—HTR6—nervous system—acquired immunodeficiency syndrome	0.00187	0.00813	CbGeAlD
Loxapine—HRH2—lung—acquired immunodeficiency syndrome	0.00184	0.00803	CbGeAlD
Loxapine—HTR2A—blood plasma—acquired immunodeficiency syndrome	0.00182	0.00793	CbGeAlD
Loxapine—HTR1E—brain—acquired immunodeficiency syndrome	0.00182	0.00792	CbGeAlD
Loxapine—DRD5—nervous system—acquired immunodeficiency syndrome	0.00182	0.00792	CbGeAlD
Loxapine—HTR6—central nervous system—acquired immunodeficiency syndrome	0.0018	0.00783	CbGeAlD
Loxapine—DRD5—central nervous system—acquired immunodeficiency syndrome	0.00175	0.00762	CbGeAlD
Loxapine—HTR3A—digestive system—acquired immunodeficiency syndrome	0.00173	0.00755	CbGeAlD
Loxapine—HRH2—nervous system—acquired immunodeficiency syndrome	0.00171	0.00744	CbGeAlD
Loxapine—HTR3A—blood—acquired immunodeficiency syndrome	0.00165	0.0072	CbGeAlD
Loxapine—HRH2—central nervous system—acquired immunodeficiency syndrome	0.00164	0.00716	CbGeAlD
Loxapine—CHRM5—nervous system—acquired immunodeficiency syndrome	0.00163	0.0071	CbGeAlD
Loxapine—CHRM4—brain—acquired immunodeficiency syndrome	0.00159	0.00695	CbGeAlD
Loxapine—CHRM5—central nervous system—acquired immunodeficiency syndrome	0.00157	0.00684	CbGeAlD
Loxapine—DRD2—retina—acquired immunodeficiency syndrome	0.00151	0.00658	CbGeAlD
Loxapine—ADRA1B—nervous system—acquired immunodeficiency syndrome	0.00149	0.00649	CbGeAlD
Loxapine—DRD3—brain—acquired immunodeficiency syndrome	0.00148	0.00646	CbGeAlD
Loxapine—HTR3A—lung—acquired immunodeficiency syndrome	0.00145	0.00631	CbGeAlD
Loxapine—ADRA1B—central nervous system—acquired immunodeficiency syndrome	0.00143	0.00625	CbGeAlD
Loxapine—HTR6—brain—acquired immunodeficiency syndrome	0.00143	0.00622	CbGeAlD
Loxapine—DRD5—brain—acquired immunodeficiency syndrome	0.00139	0.00605	CbGeAlD
Loxapine—DRD1—nervous system—acquired immunodeficiency syndrome	0.00139	0.00605	CbGeAlD
Loxapine—HTR3A—nervous system—acquired immunodeficiency syndrome	0.00134	0.00584	CbGeAlD
Loxapine—DRD1—central nervous system—acquired immunodeficiency syndrome	0.00134	0.00582	CbGeAlD
Loxapine—HTR1B—spinal cord—acquired immunodeficiency syndrome	0.00133	0.00582	CbGeAlD
Loxapine—SLC6A3—spinal cord—acquired immunodeficiency syndrome	0.00132	0.00577	CbGeAlD
Loxapine—SLC6A4—digestive system—acquired immunodeficiency syndrome	0.00132	0.00576	CbGeAlD
Loxapine—HRH2—brain—acquired immunodeficiency syndrome	0.0013	0.00568	CbGeAlD
Loxapine—HTR3A—central nervous system—acquired immunodeficiency syndrome	0.00129	0.00563	CbGeAlD
Loxapine—HTR2C—spinal cord—acquired immunodeficiency syndrome	0.00128	0.00558	CbGeAlD
Loxapine—HRH2—lymph node—acquired immunodeficiency syndrome	0.00126	0.00549	CbGeAlD
Loxapine—SLC6A4—blood—acquired immunodeficiency syndrome	0.00126	0.00549	CbGeAlD
Loxapine—CHRM5—brain—acquired immunodeficiency syndrome	0.00125	0.00543	CbGeAlD
Loxapine—SLC6A4—spinal cord—acquired immunodeficiency syndrome	0.00121	0.00529	CbGeAlD
Loxapine—SLC6A3—lung—acquired immunodeficiency syndrome	0.0012	0.00525	CbGeAlD
Loxapine—CHRM3—digestive system—acquired immunodeficiency syndrome	0.00118	0.00514	CbGeAlD
Loxapine—ADRB1—lung—acquired immunodeficiency syndrome	0.00114	0.00498	CbGeAlD
Loxapine—ADRA1B—brain—acquired immunodeficiency syndrome	0.00114	0.00496	CbGeAlD
Loxapine—HTR1B—nervous system—acquired immunodeficiency syndrome	0.00112	0.0049	CbGeAlD
Loxapine—HTR7—digestive system—acquired immunodeficiency syndrome	0.00112	0.00489	CbGeAlD
Loxapine—CHRM2—nervous system—acquired immunodeficiency syndrome	0.00112	0.00488	CbGeAlD
Loxapine—SLC6A3—nervous system—acquired immunodeficiency syndrome	0.00111	0.00486	CbGeAlD
Loxapine—SLC6A4—lung—acquired immunodeficiency syndrome	0.0011	0.00481	CbGeAlD
Loxapine—CHRM1—lung—acquired immunodeficiency syndrome	0.0011	0.00479	CbGeAlD
Loxapine—ADRA1A—lymphoid tissue—acquired immunodeficiency syndrome	0.00109	0.00477	CbGeAlD
Loxapine—HTR1D—nervous system—acquired immunodeficiency syndrome	0.00109	0.00475	CbGeAlD
Loxapine—HTR1B—central nervous system—acquired immunodeficiency syndrome	0.00108	0.00472	CbGeAlD
Loxapine—HTR2C—nervous system—acquired immunodeficiency syndrome	0.00108	0.0047	CbGeAlD
Loxapine—HTR1A—spinal cord—acquired immunodeficiency syndrome	0.00108	0.00469	CbGeAlD
Loxapine—CHRM2—central nervous system—acquired immunodeficiency syndrome	0.00108	0.00469	CbGeAlD
Loxapine—SLC6A3—central nervous system—acquired immunodeficiency syndrome	0.00107	0.00468	CbGeAlD
Loxapine—HTR7—blood—acquired immunodeficiency syndrome	0.00107	0.00466	CbGeAlD
Loxapine—DRD1—brain—acquired immunodeficiency syndrome	0.00106	0.00462	CbGeAlD
Loxapine—ADRB1—nervous system—acquired immunodeficiency syndrome	0.00106	0.00461	CbGeAlD
Loxapine—HTR1D—central nervous system—acquired immunodeficiency syndrome	0.00105	0.00457	CbGeAlD
Loxapine—HTR2C—central nervous system—acquired immunodeficiency syndrome	0.00104	0.00452	CbGeAlD
Loxapine—ADRA1A—blood—acquired immunodeficiency syndrome	0.00103	0.00449	CbGeAlD
Loxapine—HTR7—spinal cord—acquired immunodeficiency syndrome	0.00103	0.00449	CbGeAlD
Loxapine—HTR3A—brain—acquired immunodeficiency syndrome	0.00102	0.00447	CbGeAlD
Loxapine—SLC6A4—nervous system—acquired immunodeficiency syndrome	0.00102	0.00445	CbGeAlD
Loxapine—ADRB1—central nervous system—acquired immunodeficiency syndrome	0.00102	0.00444	CbGeAlD
Loxapine—CHRM1—nervous system—acquired immunodeficiency syndrome	0.00102	0.00444	CbGeAlD
Loxapine—HTR2A—retina—acquired immunodeficiency syndrome	0.000995	0.00434	CbGeAlD
Loxapine—SLC6A4—central nervous system—acquired immunodeficiency syndrome	0.000984	0.00429	CbGeAlD
Loxapine—ADRA2C—blood—acquired immunodeficiency syndrome	0.000982	0.00428	CbGeAlD
Loxapine—CHRM1—central nervous system—acquired immunodeficiency syndrome	0.00098	0.00427	CbGeAlD
Loxapine—SLC6A2—lung—acquired immunodeficiency syndrome	0.000971	0.00424	CbGeAlD
Loxapine—ADRA2C—spinal cord—acquired immunodeficiency syndrome	0.000946	0.00412	CbGeAlD
Loxapine—HTR7—lung—acquired immunodeficiency syndrome	0.000936	0.00408	CbGeAlD
Loxapine—CHRM3—nervous system—acquired immunodeficiency syndrome	0.000911	0.00397	CbGeAlD
Loxapine—ADRA2C—vagina—acquired immunodeficiency syndrome	0.00091	0.00397	CbGeAlD
Loxapine—HTR1A—nervous system—acquired immunodeficiency syndrome	0.000907	0.00396	CbGeAlD
Loxapine—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.000901	0.00185	CcSEcCtD
Loxapine—SLC6A2—nervous system—acquired immunodeficiency syndrome	0.000899	0.00392	CbGeAlD
Loxapine—Tension—Ritonavir—acquired immunodeficiency syndrome	0.000898	0.00184	CcSEcCtD
Loxapine—Feeling abnormal—Abacavir—acquired immunodeficiency syndrome	0.000897	0.00184	CcSEcCtD
Loxapine—Dysgeusia—Ritonavir—acquired immunodeficiency syndrome	0.000896	0.00184	CcSEcCtD
Loxapine—Convulsion—Efavirenz—acquired immunodeficiency syndrome	0.000896	0.00184	CcSEcCtD
Loxapine—Alopecia—Saquinavir—acquired immunodeficiency syndrome	0.000894	0.00183	CcSEcCtD
Loxapine—Oedema—Indinavir—acquired immunodeficiency syndrome	0.000893	0.00183	CcSEcCtD
Loxapine—Hypertension—Efavirenz—acquired immunodeficiency syndrome	0.000893	0.00183	CcSEcCtD
Loxapine—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.000888	0.00182	CcSEcCtD
Loxapine—Syncope—Delavirdine—acquired immunodeficiency syndrome	0.000887	0.00182	CcSEcCtD
Loxapine—Leukopenia—Delavirdine—acquired immunodeficiency syndrome	0.000886	0.00181	CcSEcCtD
Loxapine—DRD2—lung—acquired immunodeficiency syndrome	0.000885	0.00386	CbGeAlD
Loxapine—Chest pain—Efavirenz—acquired immunodeficiency syndrome	0.00088	0.0018	CcSEcCtD
Loxapine—Rash—Amprenavir—acquired immunodeficiency syndrome	0.00088	0.0018	CcSEcCtD
Loxapine—Muscle spasms—Ritonavir—acquired immunodeficiency syndrome	0.00088	0.0018	CcSEcCtD
Loxapine—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.00088	0.0018	CcSEcCtD
Loxapine—Shock—Indinavir—acquired immunodeficiency syndrome	0.000879	0.0018	CcSEcCtD
Loxapine—CHRM3—central nervous system—acquired immunodeficiency syndrome	0.000877	0.00382	CbGeAlD
Loxapine—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.000876	0.0018	CcSEcCtD
Loxapine—Headache—Amprenavir—acquired immunodeficiency syndrome	0.000875	0.00179	CcSEcCtD
Loxapine—Thrombocytopenia—Indinavir—acquired immunodeficiency syndrome	0.000875	0.00179	CcSEcCtD
Loxapine—HTR1A—central nervous system—acquired immunodeficiency syndrome	0.000873	0.00381	CbGeAlD
Loxapine—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.00087	0.00178	CcSEcCtD
Loxapine—Loss of consciousness—Delavirdine—acquired immunodeficiency syndrome	0.00087	0.00178	CcSEcCtD
Loxapine—Insomnia—Zidovudine—acquired immunodeficiency syndrome	0.000869	0.00178	CcSEcCtD
Loxapine—HTR7—nervous system—acquired immunodeficiency syndrome	0.000867	0.00378	CbGeAlD
Loxapine—SLC6A2—central nervous system—acquired immunodeficiency syndrome	0.000866	0.00378	CbGeAlD
Loxapine—Cough—Delavirdine—acquired immunodeficiency syndrome	0.000863	0.00177	CcSEcCtD
Loxapine—Paraesthesia—Zidovudine—acquired immunodeficiency syndrome	0.000862	0.00177	CcSEcCtD
Loxapine—Dysgeusia—Saquinavir—acquired immunodeficiency syndrome	0.000862	0.00177	CcSEcCtD
Loxapine—Vision blurred—Ritonavir—acquired immunodeficiency syndrome	0.000862	0.00177	CcSEcCtD
Loxapine—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.000861	0.00176	CcSEcCtD
Loxapine—ADRA2C—lung—acquired immunodeficiency syndrome	0.00086	0.00375	CbGeAlD
Loxapine—HTR1B—brain—acquired immunodeficiency syndrome	0.000859	0.00375	CbGeAlD
Loxapine—Tremor—Ritonavir—acquired immunodeficiency syndrome	0.000857	0.00176	CcSEcCtD
Loxapine—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.000856	0.00175	CcSEcCtD
Loxapine—CHRM2—brain—acquired immunodeficiency syndrome	0.000855	0.00373	CbGeAlD
Loxapine—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.000854	0.00175	CcSEcCtD
Loxapine—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.000854	0.00175	CcSEcCtD
Loxapine—Alopecia—Lamivudine—acquired immunodeficiency syndrome	0.000853	0.00175	CcSEcCtD
Loxapine—SLC6A3—brain—acquired immunodeficiency syndrome	0.000852	0.00372	CbGeAlD
Loxapine—Confusional state—Efavirenz—acquired immunodeficiency syndrome	0.000851	0.00174	CcSEcCtD
Loxapine—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	0.000847	0.00174	CcSEcCtD
Loxapine—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.000843	0.00173	CcSEcCtD
Loxapine—Chest pain—Delavirdine—acquired immunodeficiency syndrome	0.000842	0.00173	CcSEcCtD
Loxapine—Agitation—Ritonavir—acquired immunodeficiency syndrome	0.000841	0.00172	CcSEcCtD
Loxapine—HRH1—digestive system—acquired immunodeficiency syndrome	0.000837	0.00365	CbGeAlD
Loxapine—ADRA1A—nervous system—acquired immunodeficiency syndrome	0.000836	0.00365	CbGeAlD
Loxapine—HTR7—central nervous system—acquired immunodeficiency syndrome	0.000835	0.00364	CbGeAlD
Loxapine—HTR1D—brain—acquired immunodeficiency syndrome	0.000832	0.00363	CbGeAlD
Loxapine—Shock—Efavirenz—acquired immunodeficiency syndrome	0.00083	0.0017	CcSEcCtD
Loxapine—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000829	0.0017	CcSEcCtD
Loxapine—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000829	0.0017	CcSEcCtD
Loxapine—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000828	0.0017	CcSEcCtD
Loxapine—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000828	0.0017	CcSEcCtD
Loxapine—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	0.000826	0.00169	CcSEcCtD
Loxapine—Tremor—Saquinavir—acquired immunodeficiency syndrome	0.000825	0.00169	CcSEcCtD
Loxapine—Tension—Lamivudine—acquired immunodeficiency syndrome	0.000824	0.00169	CcSEcCtD
Loxapine—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000824	0.00169	CcSEcCtD
Loxapine—HTR2C—brain—acquired immunodeficiency syndrome	0.000824	0.00359	CbGeAlD
Loxapine—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000824	0.00169	CcSEcCtD
Loxapine—Dysgeusia—Lamivudine—acquired immunodeficiency syndrome	0.000823	0.00169	CcSEcCtD
Loxapine—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000821	0.00168	CcSEcCtD
Loxapine—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000821	0.00168	CcSEcCtD
Loxapine—Syncope—Ritonavir—acquired immunodeficiency syndrome	0.000821	0.00168	CcSEcCtD
Loxapine—DRD2—nervous system—acquired immunodeficiency syndrome	0.00082	0.00357	CbGeAlD
Loxapine—Leukopenia—Ritonavir—acquired immunodeficiency syndrome	0.000819	0.00168	CcSEcCtD
Loxapine—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000817	0.00167	CcSEcCtD
Loxapine—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.000814	0.00167	CcSEcCtD
Loxapine—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000814	0.00167	CcSEcCtD
Loxapine—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.00081	0.00166	CcSEcCtD
Loxapine—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000809	0.00166	CcSEcCtD
Loxapine—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.000809	0.00166	CcSEcCtD
Loxapine—ADRB1—brain—acquired immunodeficiency syndrome	0.000808	0.00352	CbGeAlD
Loxapine—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000808	0.00166	CcSEcCtD
Loxapine—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000808	0.00166	CcSEcCtD
Loxapine—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000808	0.00165	CcSEcCtD
Loxapine—ADRA1A—central nervous system—acquired immunodeficiency syndrome	0.000805	0.00351	CbGeAlD
Loxapine—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.000804	0.00165	CcSEcCtD
Loxapine—Rash—Didanosine—acquired immunodeficiency syndrome	0.000803	0.00164	CcSEcCtD
Loxapine—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.000802	0.00164	CcSEcCtD
Loxapine—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000802	0.00164	CcSEcCtD
Loxapine—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000802	0.00164	CcSEcCtD
Loxapine—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000798	0.00164	CcSEcCtD
Loxapine—Headache—Didanosine—acquired immunodeficiency syndrome	0.000797	0.00163	CcSEcCtD
Loxapine—ADRA2C—nervous system—acquired immunodeficiency syndrome	0.000797	0.00347	CbGeAlD
Loxapine—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000796	0.00163	CcSEcCtD
Loxapine—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000795	0.00163	CcSEcCtD
Loxapine—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000794	0.00163	CcSEcCtD
Loxapine—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000794	0.00163	CcSEcCtD
Loxapine—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000793	0.00162	CcSEcCtD
Loxapine—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000793	0.00162	CcSEcCtD
Loxapine—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000792	0.00162	CcSEcCtD
Loxapine—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000791	0.00162	CcSEcCtD
Loxapine—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.00079	0.00162	CcSEcCtD
Loxapine—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.00079	0.00162	CcSEcCtD
Loxapine—DRD2—central nervous system—acquired immunodeficiency syndrome	0.000789	0.00344	CbGeAlD
Loxapine—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	0.000788	0.00162	CcSEcCtD
Loxapine—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000788	0.00162	CcSEcCtD
Loxapine—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000787	0.00161	CcSEcCtD
Loxapine—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000784	0.00161	CcSEcCtD
Loxapine—ADRA2A—blood—acquired immunodeficiency syndrome	0.000783	0.00342	CbGeAlD
Loxapine—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000782	0.0016	CcSEcCtD
Loxapine—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000781	0.0016	CcSEcCtD
Loxapine—SLC6A4—brain—acquired immunodeficiency syndrome	0.000781	0.00341	CbGeAlD
Loxapine—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000779	0.0016	CcSEcCtD
Loxapine—CHRM1—brain—acquired immunodeficiency syndrome	0.000778	0.00339	CbGeAlD
Loxapine—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000774	0.00159	CcSEcCtD
Loxapine—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000771	0.00158	CcSEcCtD
Loxapine—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.00077	0.00158	CcSEcCtD
Loxapine—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.00077	0.00158	CcSEcCtD
Loxapine—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000768	0.00157	CcSEcCtD
Loxapine—ADRA2C—central nervous system—acquired immunodeficiency syndrome	0.000767	0.00335	CbGeAlD
Loxapine—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000764	0.00157	CcSEcCtD
Loxapine—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000763	0.00156	CcSEcCtD
Loxapine—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000763	0.00156	CcSEcCtD
Loxapine—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000762	0.00156	CcSEcCtD
Loxapine—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.00076	0.00156	CcSEcCtD
Loxapine—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000758	0.00155	CcSEcCtD
Loxapine—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000756	0.00155	CcSEcCtD
Loxapine—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000755	0.00155	CcSEcCtD
Loxapine—ADRA2A—spinal cord—acquired immunodeficiency syndrome	0.000755	0.00329	CbGeAlD
Loxapine—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000753	0.00154	CcSEcCtD
Loxapine—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000753	0.00154	CcSEcCtD
Loxapine—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000752	0.00154	CcSEcCtD
Loxapine—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	0.000752	0.00154	CcSEcCtD
Loxapine—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.00075	0.00154	CcSEcCtD
Loxapine—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.00075	0.00154	CcSEcCtD
Loxapine—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000747	0.00153	CcSEcCtD
Loxapine—HRH1—vagina—acquired immunodeficiency syndrome	0.000739	0.00322	CbGeAlD
Loxapine—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000738	0.00151	CcSEcCtD
Loxapine—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000736	0.00151	CcSEcCtD
Loxapine—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000735	0.00151	CcSEcCtD
Loxapine—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000733	0.0015	CcSEcCtD
Loxapine—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000733	0.0015	CcSEcCtD
Loxapine—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000733	0.0015	CcSEcCtD
Loxapine—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000732	0.0015	CcSEcCtD
Loxapine—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000731	0.0015	CcSEcCtD
Loxapine—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000731	0.0015	CcSEcCtD
Loxapine—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.00073	0.0015	CcSEcCtD
Loxapine—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000729	0.00149	CcSEcCtD
Loxapine—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000729	0.00149	CcSEcCtD
Loxapine—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000728	0.00149	CcSEcCtD
Loxapine—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000728	0.00149	CcSEcCtD
Loxapine—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000728	0.00149	CcSEcCtD
Loxapine—ADRA2A—vagina—acquired immunodeficiency syndrome	0.000726	0.00317	CbGeAlD
Loxapine—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000725	0.00149	CcSEcCtD
Loxapine—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000725	0.00149	CcSEcCtD
Loxapine—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000722	0.00148	CcSEcCtD
Loxapine—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000722	0.00148	CcSEcCtD
Loxapine—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000721	0.00148	CcSEcCtD
Loxapine—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.00072	0.00148	CcSEcCtD
Loxapine—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.00072	0.00148	CcSEcCtD
Loxapine—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000719	0.00147	CcSEcCtD
Loxapine—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000718	0.00147	CcSEcCtD
Loxapine—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000717	0.00147	CcSEcCtD
Loxapine—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000715	0.00147	CcSEcCtD
Loxapine—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000707	0.00145	CcSEcCtD
Loxapine—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000705	0.00144	CcSEcCtD
Loxapine—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000705	0.00144	CcSEcCtD
Loxapine—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000704	0.00144	CcSEcCtD
Loxapine—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000703	0.00144	CcSEcCtD
Loxapine—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.0007	0.00143	CcSEcCtD
Loxapine—HTR2A—digestive system—acquired immunodeficiency syndrome	0.000699	0.00305	CbGeAlD
Loxapine—HRH1—lung—acquired immunodeficiency syndrome	0.000699	0.00305	CbGeAlD
Loxapine—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000699	0.00143	CcSEcCtD
Loxapine—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000698	0.00143	CcSEcCtD
Loxapine—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000698	0.00143	CcSEcCtD
Loxapine—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000697	0.00143	CcSEcCtD
Loxapine—Rash—Stavudine—acquired immunodeficiency syndrome	0.000697	0.00143	CcSEcCtD
Loxapine—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000696	0.00143	CcSEcCtD
Loxapine—CHRM3—brain—acquired immunodeficiency syndrome	0.000696	0.00304	CbGeAlD
Loxapine—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000696	0.00143	CcSEcCtD
Loxapine—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000695	0.00143	CcSEcCtD
Loxapine—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000694	0.00142	CcSEcCtD
Loxapine—HTR1A—brain—acquired immunodeficiency syndrome	0.000693	0.00302	CbGeAlD
Loxapine—Headache—Stavudine—acquired immunodeficiency syndrome	0.000692	0.00142	CcSEcCtD
Loxapine—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000692	0.00142	CcSEcCtD
Loxapine—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000691	0.00142	CcSEcCtD
Loxapine—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000691	0.00142	CcSEcCtD
Loxapine—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000689	0.00141	CcSEcCtD
Loxapine—SLC6A2—brain—acquired immunodeficiency syndrome	0.000688	0.003	CbGeAlD
Loxapine—ADRA2A—lung—acquired immunodeficiency syndrome	0.000687	0.00299	CbGeAlD
Loxapine—Rash—Abacavir—acquired immunodeficiency syndrome	0.000686	0.00141	CcSEcCtD
Loxapine—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000686	0.00141	CcSEcCtD
Loxapine—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000686	0.00141	CcSEcCtD
Loxapine—Headache—Abacavir—acquired immunodeficiency syndrome	0.000682	0.0014	CcSEcCtD
Loxapine—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.00068	0.00139	CcSEcCtD
Loxapine—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.00068	0.00139	CcSEcCtD
Loxapine—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000675	0.00138	CcSEcCtD
Loxapine—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000675	0.00138	CcSEcCtD
Loxapine—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000672	0.00138	CcSEcCtD
Loxapine—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000672	0.00138	CcSEcCtD
Loxapine—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.000671	0.00138	CcSEcCtD
Loxapine—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000671	0.00137	CcSEcCtD
Loxapine—HTR2A—blood—acquired immunodeficiency syndrome	0.000666	0.0029	CbGeAlD
Loxapine—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000666	0.00136	CcSEcCtD
Loxapine—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000665	0.00136	CcSEcCtD
Loxapine—SLC6A2—lymph node—acquired immunodeficiency syndrome	0.000664	0.0029	CbGeAlD
Loxapine—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000664	0.00136	CcSEcCtD
Loxapine—HTR7—brain—acquired immunodeficiency syndrome	0.000663	0.00289	CbGeAlD
Loxapine—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000658	0.00135	CcSEcCtD
Loxapine—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000658	0.00135	CcSEcCtD
Loxapine—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000656	0.00135	CcSEcCtD
Loxapine—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.00065	0.00133	CcSEcCtD
Loxapine—HRH1—nervous system—acquired immunodeficiency syndrome	0.000647	0.00282	CbGeAlD
Loxapine—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000647	0.00133	CcSEcCtD
Loxapine—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000645	0.00132	CcSEcCtD
Loxapine—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000645	0.00132	CcSEcCtD
Loxapine—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000644	0.00132	CcSEcCtD
Loxapine—HTR2A—spinal cord—acquired immunodeficiency syndrome	0.000642	0.0028	CbGeAlD
Loxapine—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000641	0.00131	CcSEcCtD
Loxapine—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000641	0.00131	CcSEcCtD
Loxapine—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000641	0.00131	CcSEcCtD
Loxapine—ADRA1A—brain—acquired immunodeficiency syndrome	0.000639	0.00279	CbGeAlD
Loxapine—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000639	0.00131	CcSEcCtD
Loxapine—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000639	0.00131	CcSEcCtD
Loxapine—ADRA2A—nervous system—acquired immunodeficiency syndrome	0.000636	0.00277	CbGeAlD
Loxapine—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000635	0.0013	CcSEcCtD
Loxapine—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000632	0.0013	CcSEcCtD
Loxapine—DRD2—brain—acquired immunodeficiency syndrome	0.000627	0.00273	CbGeAlD
Loxapine—HRH1—central nervous system—acquired immunodeficiency syndrome	0.000623	0.00272	CbGeAlD
Loxapine—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000622	0.00127	CcSEcCtD
Loxapine—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000621	0.00127	CcSEcCtD
Loxapine—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.00062	0.00127	CcSEcCtD
Loxapine—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.00062	0.00127	CcSEcCtD
Loxapine—HTR2A—vagina—acquired immunodeficiency syndrome	0.000617	0.00269	CbGeAlD
Loxapine—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000616	0.00126	CcSEcCtD
Loxapine—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000615	0.00126	CcSEcCtD
Loxapine—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000615	0.00126	CcSEcCtD
Loxapine—ADRA2A—central nervous system—acquired immunodeficiency syndrome	0.000612	0.00267	CbGeAlD
Loxapine—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000611	0.00125	CcSEcCtD
Loxapine—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000611	0.00125	CcSEcCtD
Loxapine—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.00061	0.00125	CcSEcCtD
Loxapine—ADRA2C—brain—acquired immunodeficiency syndrome	0.000609	0.00266	CbGeAlD
Loxapine—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000606	0.00124	CcSEcCtD
Loxapine—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000606	0.00124	CcSEcCtD
Loxapine—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000605	0.00124	CcSEcCtD
Loxapine—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000602	0.00123	CcSEcCtD
Loxapine—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000597	0.00122	CcSEcCtD
Loxapine—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000595	0.00122	CcSEcCtD
Loxapine—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000592	0.00121	CcSEcCtD
Loxapine—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000592	0.00121	CcSEcCtD
Loxapine—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000591	0.00121	CcSEcCtD
Loxapine—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000591	0.00121	CcSEcCtD
Loxapine—ADRA2C—lymph node—acquired immunodeficiency syndrome	0.000589	0.00257	CbGeAlD
Loxapine—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000586	0.0012	CcSEcCtD
Loxapine—HTR2A—lung—acquired immunodeficiency syndrome	0.000584	0.00255	CbGeAlD
Loxapine—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000579	0.00119	CcSEcCtD
Loxapine—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000571	0.00117	CcSEcCtD
Loxapine—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000571	0.00117	CcSEcCtD
Loxapine—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000568	0.00116	CcSEcCtD
Loxapine—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000565	0.00116	CcSEcCtD
Loxapine—Rash—Indinavir—acquired immunodeficiency syndrome	0.000563	0.00115	CcSEcCtD
Loxapine—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000563	0.00115	CcSEcCtD
Loxapine—Headache—Indinavir—acquired immunodeficiency syndrome	0.00056	0.00115	CcSEcCtD
Loxapine—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000558	0.00114	CcSEcCtD
Loxapine—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.00055	0.00113	CcSEcCtD
Loxapine—HTR2A—nervous system—acquired immunodeficiency syndrome	0.000541	0.00236	CbGeAlD
Loxapine—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000537	0.0011	CcSEcCtD
Loxapine—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000536	0.0011	CcSEcCtD
Loxapine—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000534	0.00109	CcSEcCtD
Loxapine—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000532	0.00109	CcSEcCtD
Loxapine—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000532	0.00109	CcSEcCtD
Loxapine—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000531	0.00109	CcSEcCtD
Loxapine—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.00053	0.00109	CcSEcCtD
Loxapine—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000529	0.00108	CcSEcCtD
Loxapine—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000528	0.00108	CcSEcCtD
Loxapine—HTR2A—central nervous system—acquired immunodeficiency syndrome	0.00052	0.00227	CbGeAlD
Loxapine—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000516	0.00106	CcSEcCtD
Loxapine—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000513	0.00105	CcSEcCtD
Loxapine—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000509	0.00104	CcSEcCtD
Loxapine—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000509	0.00104	CcSEcCtD
Loxapine—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000509	0.00104	CcSEcCtD
Loxapine—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000506	0.00104	CcSEcCtD
Loxapine—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000505	0.00104	CcSEcCtD
Loxapine—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000501	0.00103	CcSEcCtD
Loxapine—HRH1—brain—acquired immunodeficiency syndrome	0.000495	0.00216	CbGeAlD
Loxapine—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000494	0.00101	CcSEcCtD
Loxapine—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000492	0.00101	CcSEcCtD
Loxapine—ADRA2A—brain—acquired immunodeficiency syndrome	0.000486	0.00212	CbGeAlD
Loxapine—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000485	0.000994	CcSEcCtD
Loxapine—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.00048	0.000983	CcSEcCtD
Loxapine—HRH1—lymph node—acquired immunodeficiency syndrome	0.000478	0.00208	CbGeAlD
Loxapine—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000475	0.000974	CcSEcCtD
Loxapine—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000475	0.000973	CcSEcCtD
Loxapine—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000471	0.000965	CcSEcCtD
Loxapine—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.00047	0.000964	CcSEcCtD
Loxapine—ADRA2A—lymph node—acquired immunodeficiency syndrome	0.00047	0.00205	CbGeAlD
Loxapine—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000468	0.000959	CcSEcCtD
Loxapine—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000457	0.000936	CcSEcCtD
Loxapine—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000453	0.000929	CcSEcCtD
Loxapine—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000453	0.000929	CcSEcCtD
Loxapine—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000453	0.000928	CcSEcCtD
Loxapine—Headache—Saquinavir—acquired immunodeficiency syndrome	0.00045	0.000923	CcSEcCtD
Loxapine—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000444	0.000909	CcSEcCtD
Loxapine—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000436	0.000893	CcSEcCtD
Loxapine—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000432	0.000886	CcSEcCtD
Loxapine—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000432	0.000885	CcSEcCtD
Loxapine—Headache—Lamivudine—acquired immunodeficiency syndrome	0.00043	0.00088	CcSEcCtD
Loxapine—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000427	0.000875	CcSEcCtD
Loxapine—HTR2A—brain—acquired immunodeficiency syndrome	0.000413	0.0018	CbGeAlD
Loxapine—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000407	0.000835	CcSEcCtD
Loxapine—HTR1D—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.21e-05	0.000149	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.21e-05	0.000149	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.19e-05	0.000148	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.19e-05	0.000148	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.18e-05	0.000148	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.18e-05	0.000148	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.18e-05	0.000148	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.18e-05	0.000148	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.17e-05	0.000148	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.16e-05	0.000147	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.15e-05	0.000147	CbGpPWpGaD
Loxapine—ADRA2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.15e-05	0.000147	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.14e-05	0.000146	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.13e-05	0.000146	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.13e-05	0.000146	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.13e-05	0.000146	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.12e-05	0.000146	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.12e-05	0.000146	CbGpPWpGaD
Loxapine—HTR6—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.12e-05	0.000146	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.12e-05	0.000146	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.12e-05	0.000146	CbGpPWpGaD
Loxapine—HTR7—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.11e-05	0.000145	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.11e-05	0.000145	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.11e-05	0.000145	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.11e-05	0.000145	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.1e-05	0.000145	CbGpPWpGaD
Loxapine—HTR1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.09e-05	0.000145	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.06e-05	0.000144	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.06e-05	0.000144	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.06e-05	0.000144	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.05e-05	0.000143	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4e-05	0.000142	CbGpPWpGaD
Loxapine—HTR1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4e-05	0.000142	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4e-05	0.000141	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4e-05	0.000141	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4e-05	0.000141	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.94e-05	0.000139	CbGpPWpGaD
Loxapine—DRD4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.94e-05	0.000139	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.93e-05	0.000139	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.93e-05	0.000139	CbGpPWpGaD
Loxapine—CHRM4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.88e-05	0.000137	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.86e-05	0.000136	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.83e-05	0.000136	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.82e-05	0.000135	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.82e-05	0.000135	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.82e-05	0.000135	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.79e-05	0.000134	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.79e-05	0.000134	CbGpPWpGaD
Loxapine—ADRA2A—Hemostasis—IL2—acquired immunodeficiency syndrome	3.79e-05	0.000134	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.79e-05	0.000134	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.78e-05	0.000134	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.77e-05	0.000133	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.77e-05	0.000133	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.76e-05	0.000133	CbGpPWpGaD
Loxapine—HTR6—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.74e-05	0.000132	CbGpPWpGaD
Loxapine—HTR7—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.73e-05	0.000132	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.72e-05	0.000132	CbGpPWpGaD
Loxapine—CHRM5—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.72e-05	0.000132	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.71e-05	0.000131	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.71e-05	0.000131	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.71e-05	0.000131	CbGpPWpGaD
Loxapine—HTR1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.71e-05	0.000131	CbGpPWpGaD
Loxapine—HRH4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.7e-05	0.000131	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.66e-05	0.000129	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.65e-05	0.000129	CbGpPWpGaD
Loxapine—HTR1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.63e-05	0.000129	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.63e-05	0.000128	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.63e-05	0.000128	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.61e-05	0.000128	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.6e-05	0.000127	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.6e-05	0.000127	CbGpPWpGaD
Loxapine—DRD4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.58e-05	0.000126	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.57e-05	0.000126	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.57e-05	0.000126	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.56e-05	0.000126	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.56e-05	0.000126	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.55e-05	0.000126	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.55e-05	0.000126	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.55e-05	0.000126	CbGpPWpGaD
Loxapine—DRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.54e-05	0.000125	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.54e-05	0.000125	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.54e-05	0.000125	CbGpPWpGaD
Loxapine—CHRM4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.53e-05	0.000125	CbGpPWpGaD
Loxapine—HTR5A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.52e-05	0.000125	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.5e-05	0.000124	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.5e-05	0.000124	CbGpPWpGaD
Loxapine—DRD3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.5e-05	0.000124	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.49e-05	0.000124	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.49e-05	0.000124	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.45e-05	0.000122	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.45e-05	0.000122	CbGpPWpGaD
Loxapine—CHRM5—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.38e-05	0.000119	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.29e-05	0.000116	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.28e-05	0.000116	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.25e-05	0.000115	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.25e-05	0.000115	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.25e-05	0.000115	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.25e-05	0.000115	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.23e-05	0.000114	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.23e-05	0.000114	CbGpPWpGaD
Loxapine—DRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.22e-05	0.000114	CbGpPWpGaD
Loxapine—HTR1E—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.22e-05	0.000114	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.21e-05	0.000113	CbGpPWpGaD
Loxapine—ADRB1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.19e-05	0.000113	CbGpPWpGaD
Loxapine—DRD3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.18e-05	0.000112	CbGpPWpGaD
Loxapine—ADRA2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.16e-05	0.000112	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.14e-05	0.000111	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.12e-05	0.000111	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.09e-05	0.000109	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.08e-05	0.000109	CbGpPWpGaD
Loxapine—HTR1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.05e-05	0.000108	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.04e-05	0.000108	CbGpPWpGaD
Loxapine—HTR2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.03e-05	0.000107	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.99e-05	0.000106	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.99e-05	0.000106	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.96e-05	0.000105	CbGpPWpGaD
Loxapine—ADRA2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.95e-05	0.000104	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.95e-05	0.000104	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.93e-05	0.000104	CbGpPWpGaD
Loxapine—ADRA1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.9e-05	0.000103	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.89e-05	0.000102	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.88e-05	0.000102	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.87e-05	0.000101	CbGpPWpGaD
Loxapine—HRH2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.87e-05	0.000101	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.86e-05	0.000101	CbGpPWpGaD
Loxapine—DRD5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.85e-05	0.000101	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.83e-05	0.0001	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.82e-05	9.96e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.77e-05	9.79e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.76e-05	9.76e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.75e-05	9.74e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.74e-05	9.69e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.72e-05	9.61e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.71e-05	9.6e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.71e-05	9.58e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.7e-05	9.55e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.69e-05	9.53e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.69e-05	9.52e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.68e-05	9.47e-05	CbGpPWpGaD
Loxapine—DRD2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.68e-05	9.47e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.67e-05	9.46e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.67e-05	9.44e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.66e-05	9.43e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.66e-05	9.4e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.66e-05	9.4e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.65e-05	9.37e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.64e-05	9.32e-05	CbGpPWpGaD
Loxapine—HTR2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.63e-05	9.31e-05	CbGpPWpGaD
Loxapine—HRH1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.63e-05	9.29e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.62e-05	9.28e-05	CbGpPWpGaD
Loxapine—CHRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.62e-05	9.26e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.62e-05	9.26e-05	CbGpPWpGaD
Loxapine—CHRM3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.61e-05	9.24e-05	CbGpPWpGaD
Loxapine—CHRM2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.59e-05	9.15e-05	CbGpPWpGaD
Loxapine—ADRA1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.58e-05	9.12e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.48e-05	8.79e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.47e-05	8.73e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.44e-05	8.65e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.44e-05	8.63e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.43e-05	8.6e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.43e-05	8.6e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.43e-05	8.6e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.42e-05	8.57e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.4e-05	8.49e-05	CbGpPWpGaD
Loxapine—ADRA2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.4e-05	8.47e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.39e-05	8.47e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.39e-05	8.46e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.39e-05	8.44e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.38e-05	8.41e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.37e-05	8.39e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.35e-05	8.31e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.34e-05	8.28e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—ALB—acquired immunodeficiency syndrome	2.33e-05	8.25e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.22e-05	7.87e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.21e-05	7.81e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.21e-05	7.81e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.2e-05	7.77e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.2e-05	7.77e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.19e-05	7.75e-05	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.18e-05	7.72e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.18e-05	7.72e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.18e-05	7.7e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.15e-05	7.59e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.14e-05	7.55e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.11e-05	7.47e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.1e-05	7.43e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.08e-05	7.37e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.07e-05	7.33e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—ALB—acquired immunodeficiency syndrome	2.07e-05	7.31e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2e-05	7.06e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.99e-05	7.02e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.9e-05	6.73e-05	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.9e-05	6.72e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—ALB—acquired immunodeficiency syndrome	1.9e-05	6.7e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.89e-05	6.69e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.88e-05	6.64e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.87e-05	6.6e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.71e-05	6.05e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.7e-05	6.02e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.69e-05	5.99e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.69e-05	5.99e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.69e-05	5.96e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.68e-05	5.95e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.64e-05	5.78e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.63e-05	5.76e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.63e-05	5.75e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.62e-05	5.73e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.58e-05	5.6e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.57e-05	5.57e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.56e-05	5.51e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.55e-05	5.48e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.44e-05	5.08e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.43e-05	5.05e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.41e-05	5e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.41e-05	4.99e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.41e-05	4.97e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.4e-05	4.97e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.4e-05	4.96e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.4e-05	4.95e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.4e-05	4.95e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.39e-05	4.93e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.39e-05	4.91e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.38e-05	4.89e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.38e-05	4.88e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.38e-05	4.87e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.3e-05	4.59e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.3e-05	4.59e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.29e-05	4.56e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.29e-05	4.55e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.28e-05	4.52e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.26e-05	4.46e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.24e-05	4.39e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.22e-05	4.33e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.17e-05	4.15e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.12e-05	3.95e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.1e-05	3.9e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1e-05	3.55e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.96e-06	3.52e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.61e-06	3.4e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.56e-06	3.38e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.3e-06	3.29e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.15e-06	3.24e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.44e-06	2.98e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.3e-06	2.94e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.28e-06	2.93e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.26e-06	2.92e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.23e-06	2.91e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.15e-06	2.88e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.13e-06	2.88e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.55e-06	2.67e-05	CbGpPWpGaD
